This group also developed and validated an IHC method for the identification of TRKA-positive clinical specimens, offering a readily applicable approach to screening CRC for TRKA overexpression and thus identifying those cases that could potentially benefit from targeted therapy [43]. Here, NTRK1 is linked to colorectal carcinoma.